David A H Whiteman

List of Publications by Year
in descending order

11	465	933447 10	1372567 10
papers	citations	h-index	g-index

11	11	11	432
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genetics in Medicine, 2011, 13, 95-101.	2.4	190
2	Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS). Molecular Genetics and Metabolism, 2011, 103, 113-120.	1.1	55
3	Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet Journal of Rare Diseases, 2017, 12, 82.	2.7	48
4	The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet Journal of Rare Diseases, 2013, 8, 101.	2.7	47
5	A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4â€“7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genetics in Medicine, 2014, 16, 435-441.	2.4	29
6	Primer on Medical Genomics Part II: Background Principles and Methods in Molecular Genetics. Mayo Clinic Proceedings, 2002, 77, 785-808.	3.0	27
7	Primer on Medical Genomics Part VIII: Essentials of Medical Genetics for the Practicing Physician. Mayo Clinic Proceedings, 2003, 78, 846-857.	3.0	22
8	Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome). Orphanet Journal of Rare Diseases, 2015, 10, 50.	2.7	22
9	Development of a mnemonic screening tool for identifying subjects with Hunter syndrome. European Journal of Pediatrics, 2013, 172, 965-970.	2.7	13
10	The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: evaluation of measurement properties. Quality of Life Research, 2013, 22, 875-884.	3.1	12
11	Idursulfase pharmacokinetics, cellular uptake, and pharmacodynamics: Effect of sialylation and manufacturing process. Engineering Reports, 2020, 2, e12271.	1.7	0